Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: Plastic mulch, basically thin sheeting placed over individual crops, is used throughout China’s arid and dusty north to improve growing conditions and boost yields by retaining moisture for crops and suppressing weeds. The country deploys about 200,000 square km (77,220 square miles) of plastic mulch, an area the size of Belarus. A notice published by several ministries on Wednesday said China would work to improve the recovery rate of plastic mulch to 80% next year and ensure there is “zero growth” in the amount of plastic mulch used. It will aim to bring recovery rates to 100% and start reducing total land coverage by 2025. The notice said China would also work to improve its monitoring capability and include mulch pollution in the performance indicators of local government officials. Manufacturers will also be put under pressure to improve product standards. China uses about 2 million to 3 million tonnes of plastic mulch every year, but waste treatment capacity amounts to just 180,000 tonnes, Yan Changrong, a researcher with the China Rural Science Institute, said at a recent forum. While the use of plastic film can boost yields significantly in the short term, unrecovered remnants eventually degrade the soil and can also contaminate crops, with Chinese exports of spinach and ginger found to contain traces of plastic, said Xu Jingeng, a parliamentary delegate for Shandong province, in a proposal submitted to the National People’s Congress in March. Handling large volumes of plastic waste has become one of China’s pressing challenges. The country’s recycling capacity stands at around 23 million to 25 million tonnes, only half of total annual plastic waste produced, according to data from the Beijing Chemistry University. The city of Shanghai is gradually restricting the use of single-use plastics in catering, and the island province of Hainan has already vowed to completely eliminate single-use plastic by 2025. [nL4N23Y1YE][nL3N20G7K1] Claim: China vows to raise recycling rates of rural plastic mulch.
China vowed to improve the recycling rates of plastic mulch used in farming, the government said on Wednesday, amid mounting concerns about soil contamination as unrecovered bits of the thin film get left behind, leaving traces in crops.

Paragraph: "There is no mention of cost. The story could have at least reported what the drug costs in its current use against blood cancer. The story did a good job of explaining both the potential benefits and harms of the drugs. This was a particular strength of this story – and made it stand out in comparison with the LA Times blog story that we also reviewed. Harms were emphasized from the outset – even in the headline – in the AP story but were never mentioned in the LA Times story. And this story reminded readers of the side effects encountered with another MS drug, Tysabri. Outstanding job on this issue by the AP. The story did a very good job of explaining the studies. There is no sign of disease-mongering in this story. Two apparently independent sources were quoted. The story did a good job comparing the new drugs with existing approaches to treat MS. Story explains that the drug is already sold to treat a rare blood cancer and stated that ""it’s too soon to know if the pills will be approved by the government or widely adopted by physicians."" It does not report, however, as the LA TImes blog did, that ""The drug company MD Serono, an affiliate of Merck, has requested approval from the Food and Drug Administration to market the tablet. However it recently received a ""refuse to file"" letter from the FDA, which means the agency is requiring additional information or data. MD Serono said it is pursuing the matter with the FDA and hopes to re-submit its application."" We think that’s a crucial piece of information that affects availability, although, of course, doctors can still prescribe it for off-label use even before the FDA acts on the new request. The novelty of ""tests of the first two oral drugs developed for treating MS"" was clear in the story. It is clear that this story did not rely on a news release." Claim: MS pills show promise and risk, studies say
Nice job explaining harms and benefits – including putting the potential risks/harms right in the headline. The appeal of an oral drug for MS is clear. The risks emphasized in this story, though, raise important questions

Paragraph: The story mentions that the Internet-based program is a “low-cost” option for treating insomnia; however, nothing more specific regarding cost is provided. It is presumed that the site will be proprietary; if so, what are the expected usage fees? The story states that compared to the control group, the treatment group woke up fewer times, spent fewer minutes awake, and had an improved score; however, the reader is not given any quantitative data or context to determine if these improvements are really meaningful in a person’s life. The story does not mention any possible harms that may be associated with managing insomnia via an Internet-based program. For example, might people develop worsening insomnia because of reinforcement of bad habits? A comment regarding the lack of identifiable harms would have been sufficient. The story accurately described the methodology and the participants; although this could have been further improved by providing more information about the control group, namely, that they did receive any type of treatment for insomnia. Additionally, the story effectively conveyed that this was a small study with a fairly homogenous population. This story does not directly address the prevalence of insomnia, but the overall tone does not suggest disease-mongering. This story includes comments from two independent experts, as well as a study co-author. The writer also mentions that the study was funded by a grant from the National Institute of Mental Health. This story includes information on the benefits of cognitive behavioral therapy and working with a therapist for treating insomnia and briefly mentions sleep medications. The story states that this Internet-based program “could one day” be an option for treating insomnia, which suggests that it is not yet ready for prime time. The story conveyed that this is a novel treatment modality for insomnia. The story does not appear to rely on a press release and quotes multiple sources that appear to be from interviews. Claim: Internet-based therapy shows promise for insomnia

This was a generally well written and balanced story about a small exploratory study on a possible new therapy for insomnia. The story effectively describes the methodology and patient population and includes expert commentary from independent sources. The story also appropriately cautions that larger studies with a more diverse patient population are warranted to verify the results and determine their generalizability. While the story meets many of our criteria, it would have been greatly improved by providing the reader with quantitative data and some context to help determine if the results translated to any real, meaningful benefit in peoples’ lives. For example, information on the Insomnia Severity Index, which was used to measure efficacy of the Internet-based program, would have been helpful. A brief exploration of cost, and of any potential harms (or lack of), would also have substantially strengthened the piece.